Open AccessConsiderations about Non-Metastatic Bladder Cancer Management During the COVID-19 Pandemic
Author(s) -
Filipe L.F. Carvalho,
Lan Anh Galloway,
Ragheed Saoud,
Piyush K. Agarwal,
Lambros Stamatakis
Publication year - 2020
Publication title -
bladder cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.27
H-Index - 19
eISSN - 2352-3735
pISSN - 2352-3727
DOI - 10.3233/blc-200311
Subject(s) - pandemic , bladder cancer , medicine , covid-19 , malignancy , cancer , disease , intensive care medicine , pathology , outbreak , infectious disease (medical specialty)
Bladder cancer is the sixth most common malignancy in the United States and is associated with high morbidity and mortality rates. To date, no guidelines have been published that clearly establish bladder cancer management recommendations during the COVID-19 pandemic. In this short commentary, we strive to outline recommendations for treatment of both muscle invasive and non-muscle invasive disease based on data from various trials and prior studies while taking into account the potential lack of hospital resources available to physicians depending on their practice location.